Skip to main
KMTS

KMTS Stock Forecast & Price Target

KMTS Analyst Ratings

Based on 5 analyst ratings
Buy
Strong Buy 20%
Buy 60%
Hold 20%
Sell 0%
Strong Sell 0%

Bulls say

Kestra Medical Techs is leveraging innovative technology to provide a non-invasive solution for early detection and prevention of cardiovascular disease. The focus on expanding coverage and investing in R&D allows for potential growth and market penetration. With FDA approval and strong financials, the company has the potential to become a leader in the MedTech industry, but competition and regulatory decisions should be monitored closely.

Bears say

Kestra Medical Techs is a commercial-stage medical device company focused on wearable defibrillators for patients at risk of sudden cardiac arrest. While it is the gold standard for managing patients with persistent high risk, its main competitor, ZOLL, has lower costs and 98% in-network penetration versus Kestra’s low 80% in a typical quarter. With a historically lower gross margin and breakeven EBIT margin, Kestra must focus on cost reduction initiatives and in-network conversions to achieve cash flow breakeven in 2H29.

KMTS has been analyzed by 5 analysts, with a consensus rating of Buy. 20% of analysts recommend a Strong Buy, 60% recommend Buy, 20% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Kestra Medical Technologies Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Kestra Medical Technologies Inc (KMTS) Forecast

Analysts have given KMTS a Buy based on their latest research and market trends.

According to 5 analysts, KMTS has a Buy consensus rating as of Sep 22, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $27.40, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $27.40, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Kestra Medical Technologies Inc (KMTS)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.